How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

885 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses

Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02289768 Recruitment Status : Completed First Posted : November 13, 2014

2014 Clinical Trials

102. Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Protocols (...) for Painless Photodynamic Therapy (PDT) of Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02124733 Recruitment Status : Recruiting First Posted : April 28, 2014 Last Update Posted : January 26, 2018 See

2014 Clinical Trials

103. Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02137785

2014 Clinical Trials

104. Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2014 Clinical Trials

105. Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02251652 Recruitment Status : Completed First Posted

2014 Clinical Trials

106. A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02120898 Recruitment Status : Completed First Posted : April 23, 2014 Last Update Posted : April 24, 2014

2014 Clinical Trials

107. Prevalence and risk factors of actinic keratoses in Germany--analysis of multisource data. (PubMed)

Prevalence and risk factors of actinic keratoses in Germany--analysis of multisource data. In Europe, only few and inconsistent data on the prevalence and treatment of actinic keratoses (AK) are available.To determine the prevalence of AK in Germany, to identify potential predictors and to estimate the number of AK cases treated in dermatological practices.In a multiple-source approach, prevalence was assessed from whole-body examinations in a cohort of 90 800 employees and from nationwide

2014 Journal of the European Academy of Dermatology and Venereology

108. Ingenol Mebutate Gel (Picato): A Novel Agent for the Treatment of Actinic Keratoses (PubMed)

Ingenol Mebutate Gel (Picato): A Novel Agent for the Treatment of Actinic Keratoses Ingenol mebutate gel (Picato) for actinic keratoses.

Full Text available with Trip Pro

2014 Pharmacy and Therapeutics

109. An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (SK-FAN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03487588 Recruitment Status : Completed First Posted : April 4, 2018 Last Update Posted : February 25, 2019 Sponsor

2018 Clinical Trials

110. Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. (PubMed)

Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. Actinic keratoses (AK) represent common cutaneous lesions, appearing in "Field cancerization areas" and potentially evolving towards invasive neoplasm. Immunosuppressed patients frequently develop numerous and aggressive AKs.In this observational study, we report our experience with topical Imiquimod 3.75% as "Field-directed therapy" in a cohort

2019 Journal of Dermatological Treatment

111. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. (PubMed)

Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. Photodynamic therapy (PDT) is a highly effective treatment option for patients with actinic keratoses (AK). However, efficacy can be reduced by insufficient illumination or hyperkeratotic nature of lesions.To investigate if PDT combined with a topical intervention is superior to monotherapy in terms of efficacy and tolerability.A systematic literature research

2019 Journal of the European Academy of Dermatology and Venereology

112. Effective treatment of disseminated superficial actinic porokeratosis with chemical peels - customary treatment for a rare disease. (PubMed)

Effective treatment of disseminated superficial actinic porokeratosis with chemical peels - customary treatment for a rare disease. Disseminated superficial actinic porokeratosis (DSAP) is a rare dermatologic disorder of the epidermis. Often misdiagnosed as chronic UV-damage or actinic keratoses, patients are treated for years with different therapeutic options with little success. Current treatment options include imiquimod, ingenol mebutate, cryosurgery, photodynamic therapy and topical

2019 Journal of Dermatological Treatment

113. Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis. (PubMed)

Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis. Actinic keratoses (AK) are common precancerous lesions of the skin due to cumulative sun exposure. A variety of interventions are available for the treatment; however, the majority of randomised controlled trials (RCTs) and meta-analyses focus on short-term efficacy outcomes. This network meta-analysis aims to investigate the long-term (> 12 months) efficacy of interventions

2019 Systematic reviews

114. Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. (PubMed)

Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Actinic keratoses (AKs) are precancerous epidermal lesions that develop on sensitive, frequently sun-exposed skin surfaces. There are very little data regarding AK prevalance. The aim of this study was to investigate the prevalence of AK and related conditions among patients in a dermatology outpatient clinic.Patients attending our dermatology outpatient clinic between January 1, 2015 and December 31, 2017

2019 Medicine

115. The more the better? An appraisal of combination therapies for actinic keratosis. (PubMed)

The more the better? An appraisal of combination therapies for actinic keratosis. Actinic keratoses (AK) are common precancerous lesions of the skin. Numerous interventions exist for the treatment of AK, including lesion- and field-directed approaches. In daily practice, different treatment modalities are often combined to maximize clearance rates. However, whether a combination therapy is preferable to monotherapy in terms of efficacy and safety has been subject of intense debate

2019 Journal of the European Academy of Dermatology and Venereology

116. The clinical course of actinic keratosis correlates with underlying molecular mechanisms. (PubMed)

The clinical course of actinic keratosis correlates with underlying molecular mechanisms. Actinic keratoses (AKs) are common premalignant skin lesions triggered by excessive ultraviolet exposure. The majority of AKs regress or persist, but some progress to squamous cell carcinomas. Biomarkers associated with their persistence, progression and regression have not been characterized.We performed skin biopsies in patients with extensive actinic damage to identify biomarkers that correlate (...) to apply sunscreens.At the molecular level, loss of E-cadherin and an increase in p53 are linked to the dynamic interplay between the persistence, progression and regression of AKs. What's already known about this topic? Actinic keratoses (AKs) are common dysplastic epidermal lesions that result from chronic and excessive ultraviolet exposure. Biomarkers associated with progression and regression of AK have not been characterized. What does this study add? Decreased E-cadherin and increased p53, Snail

2019 British Journal of Dermatology

117. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. (PubMed)

Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. Ingenol mebutate is the active agent (a macrocyclic diterpene ester) in the sap of the plant Euphorbia peplus. This herb has been used as a traditional remedy for several different skin lesions, including skin cancers.To assess 12-month recurrence rates and safety associated with ingenol mebutate gel treatment in patients who previously had achieved complete clearance of actinic keratoses.The treatment (...) area was observed for recurrence for 12 months after the original study. Patients were treated in an outpatient setting.Patients received ingenol mebutate gel, 0.015%, daily for 3 consecutive days for actinic keratoses on the face or scalp or ingenol mebutate gel, 0.05%, daily for 2 consecutive days for actinic keratoses on the trunk or extremities. Study participants had achieved complete clearance in a prespecified 25-cm2 area at day 57 of their original trial.Recurrence rates and safety were

Full Text available with Trip Pro

2013 JAMA dermatology (Chicago, Ill.)

118. Intensified fractional CO2 laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative trial on dorsal hands. (PubMed)

Intensified fractional CO2 laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative trial on dorsal hands. Photodynamic therapy (PDT) is a well-documented treatment for actinic keratosis (AK), but achieves inferior efficacy in organ transplant recipients (OTRs), particularly in acral regions. Ablative fractional laser (AFXL) intensifies the PDT response and may improve

Full Text available with Trip Pro

2013 British Journal of Dermatology

119. Topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid: Randomized controlled trial with six months follow-up. (PubMed)

Topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid: Randomized controlled trial with six months follow-up. Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) is an effective treatment for actinic keratosis (AK) with some transient adverse events.The purpose of the study was to evaluate the efficacy and side effects of two different light doses when treating AKs with ALA-PDT on the face/scalp.Thirty-eight patients with two histologically confirmed AKs were

2013 Journal of Dermatological Treatment

120. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. (PubMed)

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. Imiquimod 3.75% and 2.5% creams were studied for the treatment of actinic keratosis (AK) of the full face or balding scalp, to determine comparable efficacy and tolerability to imiquimod 5% cream.In two identical multicenter, randomized, double-blind, placebo controlled studies. Adult subjects with 5 to 20 visible lesions, or palpable AKs in an area

2013 Journal of drugs in dermatology : JDD

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>